Skip to main content
Zhejiang Cheng Yi Pharmaceutical Co.,Ltd. logo

Zhejiang Cheng Yi Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 603811 ISIN · CNE100002YC7 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 812 across all filing types
Latest filing 2026-05-22 Call Transcript
Country CN China
Listing Shanghai Stock Exchange 603811

About Zhejiang Cheng Yi Pharmaceutical Co.,Ltd.

http://en.chengyipharma.com/

Zhejiang Cheng Yi Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and distribution of pharmaceutical products. The company's portfolio encompasses active pharmaceutical ingredients (APIs) and finished dosage forms, including capsules, injections, and tablets. A primary focus is on orthopedic health, where it is a significant producer of glucosamine hydrochloride. Other key therapeutic areas include anti-viral treatments, immunosuppressants, and cardiovascular medications. The company maintains high quality standards through rigorous adherence to Good Manufacturing Practice (GMP) guidelines and international certifications. Its operations integrate advanced chemical synthesis and biotechnology to serve global markets, providing essential medicines such as ribavirin and azathioprine.

Recent filings

Filing Released Lang Actions
浙江诚意药业股份有限公司关于2025年年度暨2026年第一季度业绩说明会召开情况的公告
Call Transcript Classification · 85% confidence The document is a summary of an investor performance explanation meeting (“业绩说明会”) including management presentations, Q&A with investors, and substantive discussion of 2025 annual and Q1 2026 results. It is not a simple earnings highlights release (ER) or a formal regulatory report, but rather a transcript/minutes of a live financial briefing akin to a conference call. This matches the Call Transcript (CT) category.
2026-05-22 Chinese
上海市锦天城律师事务所关于浙江诚意药业股份有限公司2025年年度股东会的法律意见书
Regulatory Filings Classification · 45% confidence The document is a full legal opinion (“法律意见书”) prepared by the company’s external counsel regarding the convening, procedures, attendance qualifications, and vote‐counting of the 2025 Annual General Meeting. It is not a financial report (e.g., Annual, Interim, Earnings), nor a proxy solicitation, nor a pure vote results notice. It is a compliance/legal document required under securities regulations (i.e., a law firm opinion confirming the legality of the AGM). There is no dedicated category for “legal opinion,” so according to the fallback hierarchy (Regulatory Filings for compliance documents, officer certifications, etc.), this should be classified as an RNS filing.
2026-05-19 Chinese
浙江诚意药业股份有限公司2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 92% confidence The document is an announcement of the resolutions passed and detailed vote results at the company’s 2025 Annual General Meeting (date, attendance, each agenda item’s voting tallies). It reports official shareholder voting outcomes, matching the definition of ‘Declaration of Voting Results & Voting Rights Announcements.’
2026-05-19 Chinese
浙江诚意药业股份有限公司关于召开2025年年度暨2026年第一季度业绩说明会的公告
Regulatory Filings Classification · 80% confidence The document is an announcement by Zhejiang Chengyi Pharmaceutical Co., Ltd. regarding the timing, format, and participation details of a 2025 annual and 2026 Q1 performance explanation meeting (“业绩说明会”). It does not contain actual financial statements or the content of a presentation, nor is it a formal report (e.g., Annual Report, Interim Report), earnings release summary, or dividend notice. It is simply a regulatory announcement of an upcoming investor event. As it does not fit the specific categories for reports or presentations themselves, it defaults to the general Regulatory Filings category.
2026-05-14 Chinese
浙江诚意药业股份有限公司2025年年度股东会会议资料
AGM Information Classification · 99% confidence The document is titled “2025年年度股东会会议资料” and provides the meeting notice, agenda, and full text of proposals for the 2025 Annual General Meeting held on May 19, 2026. It contains materials prepared for shareholder review at the AGM, including board work report, annual report summary, profit distribution plan, financing proposals, governance changes, and related resolutions. This is exactly the AGM presentation and materials packet rather than a standalone financial report or announcement of publication. Therefore, it classifies as AGM Information (AGM-R).
2026-05-12 Chinese
浙江诚意药业股份有限公司章程（2026年4月修订）
Governance Information Classification · 98% confidence The document is the full Articles of Association (Company Charter) of Zhejiang Chengyi Pharmaceutical Co., Ltd., detailing the company’s internal rules, shareholder meeting procedures, board and management structures, share issuance and transfer rules, and governance mechanisms. This corresponds directly to ‘Governance Information’ which covers a company’s internal rules and governance practices. It is not an announcement or summary of another report but the substantive charter itself.
2026-04-23 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.